Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis

European Journal of Cancer

Volumn 83, Issue , 2017, Pages 71-79

  Zhang, Sheng ^a   Liang, Fei ^a   Li, Wenfeng ^b   Wang, Qing ^b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

Ipilimumab; Randomised controlled trials; Treatment related death

Indexed keywords

IPILIMUMAB; PLACEBO; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; COLITIS; DIARRHEA; DRUG MEGADOSE; ESOPHAGUS CANCER; GASTROESOPHAGEAL JUNCTION; GASTROESOPHAGEAL JUNCTION CANCER; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; LOW DRUG DOSE; LUNG CANCER; MALE; MALIGNANT NEOPLASM; MELANOMA; META ANALYSIS; MORTALITY RISK; PERFORATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; SYSTEMATIC REVIEW; MORTALITY; NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; INCIDENCE; NEOPLASMS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85024098202     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.06.021     Document Type: Article

References (32)

1. Lazarou, J., Pomeranz, B.H., Corey, P.N., Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:15 (1998), 1200–1205.
2. Choueiri, T.K., Je, Y., Sonpavde, G., et al. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Ann Oncol 24:8 (2013), 2092–2097.
3. Schutz, F.A., Je, Y., Richards, C.J., Choueiri, T.K., Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 30:8 (2012), 871–877.
4. Ranpura, V., Hapani, S., Wu, S., Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305:5 (2011), 487–494.
5. Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
6. Romano, E., Kusio-Kobialka, M., Foukas, P.G., et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A 112:19 (2015), 6140–6145.
7. Robert, C., Thomas, L., Bondarenko, I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:26 (2011), 2517–2526.
8. Antonia, S.J., Lopez-Martin, J.A., Bendell, J., et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17:7 (2016), 883–895.
9. Hellmann, M.D., Rizvi, N.A., Goldman, J.W., et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18:1 (2017), 31–41.
10. Weber, J.S., Kahler, K.C., Hauschild, A., Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:21 (2012), 2691–2697.
11. Horvat, T.Z., Adel, N.G., Dang, T.O., et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering Cancer Center. J Clin Oncol 33:28 (2015), 3193–3198.
12. Beer, T.M., Kwon, E.D., Drake, C.G., et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-Naive castration-resistant prostate cancer. J Clin Oncol 35:1 (2017), 40–47.
13. US Food and Drug Administration. Food and Drug Administration Amendments Act (FDAAA) of 2007. US Public Law 110-85 section 801. www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf. [Accessd 13 November 2016].
14. Freeman, M.F.T.J., Transformations related to the angular and the square root. Ann Math Stats 21 (1950), 607–611.
15. Bradburn, M.J., Deeks, J.J., Berlin, J.A., Russell Localio, A., Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26:1 (2007), 53–77.
16. Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375:19 (2016), 1845–1855.
17. Lynch, T.J., Bondarenko, I., Luft, A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30:17 (2012), 2046–2054.
18. Kwon, E.D., Drake, C.G., Scher, H.I., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:7 (2014), 700–712.
19. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.
20. Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
21. Reck, M., Bondarenko, I., Luft, A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24:1 (2013), 75–83.
22. Reck, M., Luft, A., Szczesna, A., et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 34:31 (2016), 3740–3748.
23. Bristol-Myers Squibb. An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy. https://clinicaltrials.gov/ct2/show/NCT01585987?term=NCT01585987. [Accessed 16 November 2016].
24. Bristol-Myers Squibb. Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin. https://clinicaltrials.gov/ct2/show/NCT01285609?term=NCT01285609. [Accessed 16 November 2016].
25. Gao, J., He, Q., Subudhi, S., et al. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 34:43 (2015), 5411–5417.
26. Weber, J.S., Dummer, R., de Pril, V., Lebbe, C., Hodi, F.S., Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119:9 (2013), 1675–1682.
27. Nalluri, S.R., Chu, D., Keresztes, R., Zhu, X., Wu, S., Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:19 (2008), 2277–2285.
28. Minor, D.R., Risk of venous thromboembolism with bevacizumab in cancer patients. JAMA, 301(14), 2009, 1434 author reply 1435–1436.
29. Je, Y., Schutz, F.A., Choueiri, T.K., Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10:10 (2009), 967–974.
30. Minor, D.R., Risk of bleeding not increased by sorafenib or sunitinib. Lancet Oncol 11:2 (2010), 112–113 author reply 113.
31. Choueiri, T.K., Schutz, F.A., Je, Y., Rosenberg, J.E., Bellmunt, J., Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28:13 (2010), 2280–2285.
32. Minor, D.R., Risk of arterial thrombosis not increased by sorafenib or sunitinib. J Clin Oncol, 28(30), 2010, e619 author reply e620.